Gemini Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare Conference

Rhea-AI Summary

Gemini Therapeutics, a clinical stage precision medicine company focused on treatments for genetically defined age-related macular degeneration (AMD), announced that CEO Jason Meyeburg will present virtually at the SVB Leerink 10th Annual Global Healthcare Conference on February 25 at 1:00 PM ET. A live webcast will be accessible on the company’s website, with a replay available for 30 days afterward.

The company's lead candidate, GEM103, targets AMD by addressing complement hyperactivity and restoring retinal health, currently under Phase 2a trials.

Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD) and linked ocular disorders, today announced that Jason Meyeburg, Chief Executive Officer of Gemini Therapeutics, is scheduled to participate virtually in the SVB Leerink 10^th Annual Global Healthcare Conference on Thursday, February 25 at 1:00 PM ET.

A live webcast of the event will be available on the "Events & Presentations" page on the Company's website. A replay of the webcast will be archived on the Company's website for 30 days following the presentation.

About Gemini Therapeutics

Gemini Therapeutics is a clinical stage precision medicine company developing novel therapeutic compounds to treat genetically defined age-related macular degeneration (AMD). Gemini’s lead candidate, GEM103, is a recombinant form of the human complement factor H protein (CFH), and is designed to address both complement hyperactivity and restore retinal health in patients with AMD. GEM103 is currently in a Phase 2a trial in dry AMD patients with a CFH risk variant. The company has generated a rich pipeline including recombinant proteins, gene therapies, and monoclonal antibodies.

For more information, visit www.geminitherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210219005014/en/

FAQ

What event will Jason Meyeburg participate in for Gemini Therapeutics?

Jason Meyeburg will participate virtually in the SVB Leerink 10th Annual Global Healthcare Conference on February 25 at 1:00 PM ET.

How can I watch the presentation by Gemini Therapeutics' CEO?

The presentation will be available via a live webcast on Gemini Therapeutics' website and archived for 30 days.

What is GEM103 developed by Gemini Therapeutics?

GEM103 is a recombinant form of the human complement factor H protein aimed at treating age-related macular degeneration.

What trials is Gemini Therapeutics conducting for GEM103?

GEM103 is currently in a Phase 2a trial targeting patients with dry AMD who have a CFH risk variant.

What is the focus of Gemini Therapeutics as a company?

Gemini Therapeutics specializes in precision medicine to develop treatments for genetically defined age-related macular degeneration and related ocular disorders.